NanoViricides (NYSE:NNVC) Downgraded to Sell Rating by StockNews.com

by · The Cerbat Gem

StockNews.com downgraded shares of NanoViricides (NYSE:NNVC – Free Report) from a hold rating to a sell rating in a report published on Friday morning.

NanoViricides Stock Performance

NanoViricides stock opened at $1.41 on Friday. The company’s 50 day simple moving average is $1.52 and its 200-day simple moving average is $1.82. The company has a market capitalization of $19.60 million, a price-to-earnings ratio of -2.06 and a beta of 0.96. NanoViricides has a 1 year low of $1.00 and a 1 year high of $3.59.

NanoViricides (NYSE:NNVC – Get Free Report) last released its quarterly earnings results on Friday, September 27th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01.

Institutional Investors Weigh In On NanoViricides

An institutional investor recently bought a new position in NanoViricides stock. Moss Adams Wealth Advisors LLC bought a new position in shares of NanoViricides, Inc. (NYSE:NNVC – Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 15,000 shares of the company’s stock, valued at approximately $26,000. Moss Adams Wealth Advisors LLC owned 0.13% of NanoViricides as of its most recent SEC filing. Institutional investors own 10.30% of the company’s stock.

NanoViricides Company Profile

(Get Free Report)

NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.

Featured Stories